[1]
G. Reka, A. Pawlak, P. Machowiec, M. Maksymowicz, and H. Piecewicz-Szczesna, “Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature”, Curr. Issues Pharm. Med. Sci., vol. 34, no. 3, pp. 138–141, Oct. 2021, doi: 10.2478/cipms-2021-0030.